---
title: "Canada's Edesa Biotech Q1 net loss widens"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275946010.md"
description: "Canada's Edesa Biotech reported a Q1 net loss of $2.2 million, an increase attributed to higher operating expenses of $2.3 million driven by R&D and administrative costs. The company plans to start recruitment for a vitiligo study in mid-2026 and is exploring commercialization pathways for paridiprubart. Analysts maintain a \"buy\" rating on the stock, with a median 12-month price target of $9.00, significantly above its recent closing price of $1.00."
datetime: "2026-02-13T21:28:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275946010.md)
  - [en](https://longbridge.com/en/news/275946010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275946010.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275946010.md) | [繁體中文](https://longbridge.com/zh-HK/news/275946010.md)


# Canada's Edesa Biotech Q1 net loss widens

)

Overview

-   Canada biopharma firm’s Q1 net loss widened to $2.2 mln, driven by higher expenses
-   Operating expenses rose to $2.3 mln due to increased R&D and admin costs

Outlook

-   Company anticipates recruitment for vitiligo study to begin midyear 2026
-   Edesa exploring accelerated commercialization pathways for paridiprubart
-   Company plans to establish investigational sites across multiple jurisdictions

Result Drivers

-   VITILIGO STUDY PREPARATION - Increased R&D expenses due to manufacturing and preparations for Phase 2 study of EB06 in vitiligo patients

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q1 EPS -$0.28

Q1 Net -$2.2

Income mln

Q1 $2.3 mln

Operatin

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Edesa Biotech Inc is $9.00, about 804.5% above its February 12 closing price of $1.00

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Edesa Biotech, Inc. (EDSA.US)](https://longbridge.com/en/quote/EDSA.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M](https://longbridge.com/en/news/277812097.md)
- [bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care](https://longbridge.com/en/news/277701323.md)
- [Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions](https://longbridge.com/en/news/277932436.md)
- [Senseonics Holdings: Q4 Earnings Insights](https://longbridge.com/en/news/277517921.md)
- [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)